A piggyback attack: Using the common cold to deliver an HIV vaccine
The best offense? CCR5 inhibitors, with one now on the market, suggest it may be a good defense
Solving the viral spike: Can structural biology find a chink in HIV's armor?
Reconstructing early HIV: The search for immunogens delves into the virus' past
Profile: A Receptive Leader: Panacos' Graham Allaway
Stem cells enjoyed a short run as potential gene therapy vehicles in the 1990s. Most approaches suffered, however, from low expression levels and low transduction efficiencies in target cells. Though researchers had developed a rich array of anti-HIV genes, including antisense and virion fusion inhibitors, RNA decoys, and short hairpin RNAs, their in vitro effectiveness did not translate into significant therapeutic effects in patients.
Today, ...